Author(s):
Badar Uddin Umar, Mainul Haque
Email(s):
runurono@gmail.com
DOI:
10.5958/0974-360X.2015.00287.5 
Address:
Badar Uddin Umar1, Mainul Haque2*
1Faculty of Medicine, AIMST University, Semeling, 08100 Bedong, Kedah, Malaysia.
2Faculty of Medicine, Universiti Sultan Zainal Abidin, Medical Campus, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Terengganu, Malaysia.
*Corresponding Author
Published In:
Volume - 8,
Issue - 11,
Year - 2015
ABSTRACT:
The safety of medicines has been a major issue involving health care delivery systems worldwide. Adverse drug reactions (ADRs) cause a huge burden accounting for considerable morbidity, mortality, andextra costs both developed and developing nations. Monitoring ADRs and pharmacovigilance (PV) is not adequate in many developing countries like Bangladesh. A literature search revealed only a few publications on ADRs in Bangladesh. These scientific reports revealed that the rate of ADRs are comparable with many countries, but the alarming issue is regulatory agencies are not much concern about the atrocities of ADRs. Despite the existing functional government organizations for monitoring ADRs which reports ADR cases to the WHO, it fails to keep pace with the current global situation. The Government of Bangladesh and other stakeholders should take up immediate initiatives in boosting up monitoring, and enhance awareness to report ADRs by the doctors, nurses, pharmacist and patients. PV studies and research on ADRs in Bangladesh should be encouraged.
Cite this article:
Badar Uddin Umar, Mainul Haque. Adverse Drug Reactions in Bangladeshi Health Care Setup: An Update. Research J. Pharm. and Tech. 8(11): Nov., 2015; Page 1598-1602. doi: 10.5958/0974-360X.2015.00287.5
Cite(Electronic):
Badar Uddin Umar, Mainul Haque. Adverse Drug Reactions in Bangladeshi Health Care Setup: An Update. Research J. Pharm. and Tech. 8(11): Nov., 2015; Page 1598-1602. doi: 10.5958/0974-360X.2015.00287.5 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2015-8-11-24
REFERENCES:
1. Helali AM, Iqbal MJ, Islam AZ, Haque M. The evolving role of pharmacovigilance and drug safety: The way forward for Bangladesh. Int J Pharmaceut Res. 2014; 6: 31-37.Available from: URL:http://www.ijpronline.com/ViewArticleDetail.aspx?ID=733
2. Abubakar AR, Simbak NB, Haque M. A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors. J Appl Pharmaceut Sci. 2014; 4: 117-27.Available from: URL:http://www.japsonline.com/admin/php/uploads/1360_pdf.pdf
3. Health System in Bangladesh: It’s Challenges and Opportunities. Available from: URL:file:///C:/Users/user/Downloads/Present_Status_of_Health_System_in_Bangladesh02.pdf
4. Rägo L, Santoso B. Drug regulation: history, present and future. In: Drug Benefits and Risks: International Textbook of Clinical Pharmacology revised 2nd Edition, 2008. Available from: URL:http://www.who.int/medicines/technical_briefing/tbs/Drug_Regulation_History_Present_Future.pdf
5. Baines DA. Problems facing the pharmaceutical industry and approaches to ensure long term viability. 2010. Available from: URL:http://repository.upenn.edu/cgi/viewcontent.cgi?article=1032&context=od_theses_msod
6. Shojania KG. Deaths due to medical error: jumbo jets or just small propeller planes? MBJ Qual Saf. 2012; 21: 709-12. Available from: URL:http://qualitysafety.bmj.com/
7. Lau DH. Improve patient safety and reduce medical errors. Hong Kong Med J. 2002; 8: 65-7. Available from: URL:www.hkmj.org/article_pdfs/hkm0202p65.pdf
8. Jewell K, McGiffert L. To Err is Human – To Delay is Deadly. Ten years later, a million lives lost, billions of dollars wasted. SafePatientProject.org. 2009. Available from: URL:http://safepatientproject.org/pdf/safepatientproject.org-to_delay_is_deadly-2009_05.pdf.
9. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. J Am Med Assoc. 1998; 279: 1200-05.Available from: URL:http://jama.jamanetwork.com/article.aspx?articleid=187436
10. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ : British Medical Journal. 2004;329(7456):15-19.Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC443443/pdf/bmj32900015.pdf
11. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. Journal of Pharmacology and Pharmacotherapeutics. 2013; 4(Suppl1):S73-S77. doi:10.4103/0976-500X.120957. Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853675/
12. Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharm. 2010;70(5):749-755. doi:10.1111/j.1365-2125.2010.03751.x. Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997315/pdf/bcp0070-0749.pdf
13. Nivya K, Kiran VSS, Ragoo N, Jayaprakashb B, Sekhar MB. Systemic review on drug related hospital admissions – A pubmed based search. Saudi Pharmaceutical Journal. 2015; 23 (1): 1–8. Available from: URL:http://www.sciencedirect.com/science/article/pii/S1319016413000509
14. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharm. 2007; 65: 210-16.Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291214/pdf/bcp0065-0210.pdf
15. Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip Toxicol. 2013; 6: 41-46.Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795320/pdf/ITX-6-041.pdf
16. Nahar N, Karim A, Paul PC, Khan TH. Response of reporting adverse drug reactions among medical practitioners. Bangladesh Med J. 2011; 4: 13-18.Available from: URL:http://www.banglajol.info/index.php/BMJ/article/view/18498/12952
17. Begum ZA, Sultana S, Umar BU, Ferdous AH, Uddin MK, Islam SMH. Study of adverse drug reactions in out-patient departments of a teaching hospital. Bangladesh J Pharmacol. 2012; 7: 104-07.Available from: URL:http://www.banglajol.info/index.php/BJP/article/view/10760/7965
18. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000; 356: 1255-59.Available from: URL:http://www.sciencedirect.com/science/article/pii/S0140673600027999#
19. Nwokike J, Ludeman E, Thumm M. Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. 2013. Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health. Available from: URL:www.siapsprogram.org
20. Al-Muntasir M, Saha D, Paul S, Rahim ZB, Hosen SMZ. Studies on pharmacovigilance in Bangladesh: Safety issues. Int J Pharm Teach Pract. 2013; 4: 613-21.Available from: URL:http://connection.ebscohost.com/c/articles/91585129/studies-pharmacovigilance-bangladesh-safety-issues
21. Al-Muntasir M, Likhan MMI, Rahim ZB, Hosen SMZ, Saha D. Past, present and future perspectives of pharmacovigilance in Bangladesh: safety issue for patient care. Mexican J Sci Res. 2013; 2: 49-58.file:///C:/Users/UDM/Downloads/11-41-1-PB.pdfAvailable from: URL:
22. Nwokike J, Ludeman E, Thumm M. Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries. Systems for Improved Access to Pharmaceuticals and Services, Center for Pharmaceutical Management, Management Sciences for Health 4301 North Fairfax Drive, Suite 400. US AID. Available from: URL:http://apps.who.int/medicinedocs/documents/s21335en/s21335en.pdf
23. Suvarna V. Phase IV of Drug Development. Perspectives in Clinical Research. 2010; 1(2):57-60. Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148611/
24. Wiktorowicz ME, Lexchin J, Paterson M, Mintzes B, Metge C, Light D, Morgan S, Holbrook A, Tamblyn R, Zaki E, Moscou K. Research networks involved in post-market pharmacosurveillance in the United States, United Kingdom, France, New Zealand, Australia, Norway and European Union: Lessons for Canada. Canadian Health Services Research Foundation. Available from: URL:http://www.patientsafetyinstitute.ca/english/research/commissionedresearch/postmarketingsurveillance/documents/post-marketing%20pharmacosurveillance%20final%20report.pdf
25. Report of an Independent Review of Access to the Yellow Card Scheme. Published by TSO (The Stationery Office), 123 Kingsway, London, WC2B 6PQ, 2004. Available from: URL:http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con2015008.pdf
26. Reddy VL, Pasha SKJ, Rathinavelu M, Reddy YP. Assessment of Knowledge, Attitude and Perception of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting among the Pharmacy Students in South India. IOSR Journal of Pharmacy and Biological Sciences. 2014; 9(2): 34-43. Available from: URL:http://iosrjournals.org/iosr-jpbs/papers/Vol9-issue2/Version-3/G09233443.pdf
27. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements. International Journal of Health Policy and Management. 2015; 4(5):295-305. doi:10.15171/ijhpm.2015.55. Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417633/pdf/IJHPM-4-295.pdf
28. Shill MC, Das AK. Medication practices in Bangladesh-Roles of pharmacist at current circumstances. Int J Pharm Pharmaceut Sci. 2011; 3: 5-8.Available from: URL:http://www.ijppsjournal.com/Vol3Suppl4/2283.pdf
29. Uzzal M. Doctors fail to report adverse drug reactions. Dhaka Tribune. 2013. Available from: URL:http://www.dhakatribune.com/safety/2013/oct/06/doctors-fail-report-adverse-drug-reactions
30. Moride Y, Haramburu F, Requejo AA, Bégaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997; 43 (2): 177-81.Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042725/pdf/bcp_0541.pdf
31. Hadi MA, Ming LC. Impact of pharmacist recruitment on ADR reporting: Malaysian experience. Southern Med Rev. 2011; 4: 55-6.Available from: URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471183/pdf/smr-04-102.pdf
32. Kamtane RA, Jayawardhani V. Knowledge, attitude and perception of physicians towards adverse drug reaction (ADR) reporting: a pharmacoepidemiological study. Asian J Pharmaceut Clin Res. 2012; 5: 210-14.Available from: URL:http://www.ajpcr.com/Vol5Suppl3/1231.pdf
33. Islam AFMS, Rahman MS. Levofloxacin-induced fatal toxic epidermal necrolysis. The Ann Pharmacother. 2005; 39: 1136-37.Available from: URL:http://www.annals.edu.sg/pdf/39VolNo8Aug2010/V39N8p660.pdf
34. Nur J, Chowdhury FR, Ahsan HAMN, Alam MB. Fatal outcome of Steven Johnson Syndrome (SJS) associated with azithromycin. Pak J Med Sci. 2008; 24: 455-57.Available from: URL:http://www.pjms.com.pk/issues/aprjun208/pdf/SJS.pdf
35. Chowdhury FR, Mohammed FR, Alam MZ, Nur Z, Hoque MA, Uddin MM, Bakar MA. Etiology and outcome of patients admitted in a tertiary level hospital with adverse drug reaction (ADR). J Dhaka Med Coll. 2008; 17: 17-21.Available from: URL:https://www.academia.edu/4940746/Etiology_and_Outcome_of_Patients_Admitted_in_Tertiary_Level_Hospital_with_Adverse_Drug_Reaction_ADR_
36. Hasan R, Akhter N, Begum M, Ali ME, Paul HK, Zakaria ASM, Rashid MM. Cutaneous morphological patterns of adverse drug reactions: a study of 50 cases. J Pak Assoc Derm. 2010; 20: 2006-11.Available from: URL:http://www.jpad.org.pk/Oct%20Dec%202010/4Original%20article%20Patternsof%20cutaneous%20adverse%20drug%20reaction.pdf
37. Khondoker L, Khan MSI. Clinical profile of cutaneous drug reactions. J Pak Assoc Derm. 2014; 24: 160-63.
Available from: URL:http://www.jpad.org.pk/April-June-2014/11.%20Original%20article%20Drug%20reaction.pdf
38. Rahman MM, Mishuk A, Halder S, Kabir AKL. Comparative analysis of adverse drug reactions in directly observed treatment short course (DOTS) in TB patients. Glob J Med Res. 2013; 13: 6-10.Available from: URL:https://globaljournals.org/GJMR_Volume13/2-Comparative-Analysis-of-Adverse.pdf
39. Haque M, Khasru MSR. Pharmacovigilance systems in Bangladesh. International conference and CME cum workshop on pharmacovigilance and rational use of medicines: an integrated approach. 26-28 Nov, 2010. Held in Lady Hardinge Medical College, Delhi-110001. Available from: URL:http://www.researchgate.net/publication/209390286_Pharmacovigilance_Bangladesh_Situation
40. Directorate General of Drug Administration. ADR monitoring in Bangladesh. Available from: URL:http://www.dgda.gov.bd/index.php/2013-03-31-04-35-57/adrm-reaction-monitoring
41. UPPSALA Monitoring Centre. Two South Asian countries join the WHO Programme 23 December 2014. Available from: URL:http://www.who-umc.org/DynPage.aspx?id=108464&mn1=7347
42. Salam A, Haque M, Helali AM, Islam MZ, Mohsena M, Rahman Z, Yesmin F, Rahman NIA, Alattaraqchi AG, Yousuf R. Comparative Study On Professionalism Of Forthcoming Medical Doctors Between Two Private Medical Colleges In Savar, Bangladesh. Int J Pharm Pharm Sci. 2013; 59(Suppl 3): 659-665. Available from: URL:http://www.ijppsjournal.com/Vol5Suppl3/7441.pdf
43. Salam A, Haque M, Islam MZ, Helali AM, Yousuf R, Yesmin F, Alattaraqchi AG, Rao USM. Comparative Study of Professionalism of Future Medical Professionals among Three Private Medical Colleges of Bangladesh. Asian J Pharm Clin Res. 2013; 6 (3): 170-179. Available from: URL: http://www.ajpcr.com/Vol6Issue3/157.pdf
44. Islam MZ , Salam A , Helali AM , Rahman Z , Dali WPEW , Ismail S , Rahman NIA , Haque M. Comparative Study of Professionalism of Future Medical Doctors Between Malaysia and Bangladesh. J App Pharm Sci. 2014; 4 (04): 066-071. Available from: URL:http://www.japsonline.com/admin/php/uploads/1229_pdf.pdf
45. Salam A , Yousuf R, Islam MZ, Yesmin F, Helali AM, Alattaraqchi AG, Rao USM, Haque M. Professionalism of future medical professionals in Universiti Sultan Zainal Abidin, Malaysia. Bangladesh J Pharmacol. 2013; 8: 124-130. Available from: URL:http://banglajol.info/index.php/BJP/article/view/14158/10108